Published in Blood Weekly, November 26th, 2009
Erythropoiesis-stimulating agents (i.e., erythropoietin and darbopoietin) stimulate red blood cell production and therefore were approved to reduce the number of blood transfusions required during chemotherapy; however, concerns about the risks of venous thromboembolism (the disease that includes deep vein thrombosis and pulmonary embolism) and mortality exist.
Dawn L. Hershman, M.D., of Columbia University Medical Center in New York, and colleagues...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.